| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2023414 | Regulatory Peptides | 2006 | 6 Pages |
The present study investigated the effect of somatostatin in the regulation of cGMP levels in rat retina and the mechanisms involved in this process. Isolated rat retinas were treated alone or in the presence of somatostatin (0.01–10 μM), BIM23014 (sst2 agonist, 0.01–10 μM), L-796,778 (sst3 agonist, 10 μM), somatostatin (0.1 μM) in combination with CYN154806 (sst2 antagonist, 1 μM), NG-methyl-l-arginine acetate salt (NMMA, inhibitor of the nitric oxide synthase (NOS), 250 μM), orthovanadate (inhibitor of tyrosine phosphatase, SHP-1, 1 μM), and arginine alone (250 μM). cGMP levels were quantified by ELISA. Immunohistochemistry studies were performed for the detection of cGMP and nNOS, while Western blot analysis was employed for the detection of SHP-1. Somatostatin increased cGMP levels in a concentration-dependent manner. This increase was inhibited by CYN154806. BIM23014 increased cGMP levels only at the concentration of 10 μM, while L-796,778 had no effect. NMMA blocked completely the somatostatin stimulated increase of cGMP levels and nNOS was detected in rat retina. cGMP immunoreactivity was observed primarily in bipolar cells only of nitroprusside-treated retinas. SHP-1 inhibition by orthovanadate reduced the somatostatin effect in a statistically significant manner. These results suggest that a SRIF/SHP-1/NO/cGMP mechanism underlies the actions of somatostatin in the retina and in its influence of retinal circuitry.
